Scanlon P W, Scott M, Segura J W
Cancer. 1983 Oct 1;52(7):1153-9. doi: 10.1002/1097-0142(19831001)52:7<1153::aid-cncr2820520705>3.0.co;2-b.
This retrospective study failed to detect a significant difference in survival rates between patients with bladder carcinoma who underwent cystectomy after short-course, low-dose radiation and those who underwent cystectomy after long-course, high-dose radiation. The authors were able to identify in the long-course--high-dose group a subset of patients with an unusually good prognosis, but this advantage was not reflected in survival rates. The value of the ability of the long-course--high-dose preoperative technique to identify a subgroup of patients with a relatively good survival rate remains to be determined. In terms of the current management of bladder cancer, this ability to identify a favorable subset of patients is probably not worth the cost and morbidity involved. If, however, adjuvant chemotherapy is to be considered, this ability might be valuable.
这项回顾性研究未能检测出接受短疗程、低剂量放疗后行膀胱切除术的膀胱癌患者与接受长疗程、高剂量放疗后行膀胱切除术的患者之间生存率的显著差异。作者能够在长疗程、高剂量组中识别出一部分预后异常良好的患者，但这一优势并未体现在生存率上。长疗程、高剂量术前技术识别出相对生存率较高患者亚组的能力的价值仍有待确定。就目前膀胱癌的治疗而言，这种识别有利患者亚组的能力可能不值得付出相关成本和带来的发病率。然而，如果要考虑辅助化疗，这种能力可能是有价值的。
